NeuroPace (NASDAQ:NPCE) Rating Lowered to Market Perform at Leerink Partners

NeuroPace (NASDAQ:NPCE) was downgraded by Leerink Partners from an “outperform” rating to a “market perform” rating in a report issued on Friday, MarketBeat.com reports. They currently have a $7.00 target price on the stock. Leerink Partners‘s price objective suggests a potential downside of 41.76% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of NeuroPace in a research report on Wednesday, July 29th. Raymond James Financial set a $21.00 price target on shares of NeuroPace in a research report on Tuesday, September 15th. Mizuho initiated coverage on shares of NeuroPace in a report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price target for the company. Finally, KeyCorp assumed coverage on shares of NeuroPace in a research report on Thursday, September 17th. They set an “overweight” rating and a $18.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $12.02 on Friday. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. The company has a market capitalization of $412.53 million, a price-to-earnings ratio of -21.09 and a beta of 1.98. NeuroPace has a twelve month low of $11.90 and a twelve month high of $19.60. The business has a 50 day simple moving average of $13.35 and a 200-day simple moving average of $14.79.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04. The firm had revenue of $22.83 million for the quarter, compared to analysts’ expectations of $22.61 million. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. As a group, equities research analysts expect that NeuroPace will post -0.67 earnings per share for the current year.

Institutional Trading of NeuroPace

Hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new position in NeuroPace during the 2nd quarter valued at approximately $41,000. Algert Global LLC grew its stake in NeuroPace by 2.9% during the 2nd quarter. Algert Global LLC now owns 184,774 shares of the company’s stock worth $2,936,000 after buying an additional 5,218 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in NeuroPace during the 2nd quarter worth $157,000. Lazard Asset Management LLC grew its stake in NeuroPace by 9.8% during the 1st quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock worth $1,635,000 after buying an additional 11,078 shares during the last quarter. Finally, Diversified Trust Co acquired a new stake in NeuroPace in the third quarter worth $153,000. Institutional investors own 78.83% of the company’s stock.

Top NeuroPace Stories

Here are a few of the latest stories about NPCE:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

NeuroPace Company Profile

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.